PMID- 28225311
OWN - NLM
STAT- MEDLINE
DCOM- 20170831
LR  - 20210204
IS  - 1530-891X (Print)
IS  - 1530-891X (Linking)
VI  - 23
IP  - 6
DP  - 2017 Jun
TI  - PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS 
      METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
PG  - 641-648
LID - 10.4158/EP161639.OR [doi]
AB  - OBJECTIVE: Duodenopancreatic neuroendocrine tumors (DP-NETs) develop in a 
      majority of patients with multiple endocrine neoplasia type 1 (MEN1) and are the 
      leading cause of death. Overall survival (OS) and prognostic factors for patients 
      with liver metastases from DP-NETs are not known. METHODS: This was a cohort 
      study using the Dutch National MEN1 database, which includes >90% of the Dutch 
      MEN1 population treated between 1990 and 2014. OS was assessed with time to event 
      analysis, and prognostic factors were evaluated. RESULTS: A total of 56% of the 
      MEN1 patients (n = 220) were diagnosed with a DP-NET, of who 34 (15%) developed 
      DP-NET liver metastases. Median age at liver metastases diagnosis was 53 years 
      (range 31-74). Of those patients, 16 patients (47%) had died after a median 
      follow-up of 4 years (range 0.3-12.3). OS at 2, 5, and 10 years were 91%, 65%, 
      and 50%, respectively. A trend towards worse survival was seen in males compared 
      to females (5-year OS 58% versus 75%, P = .07) and also in patients with multiple 
      liver metastases compared to patients with solitary liver metastasis (59 versus 
      83%, P = .09). CONCLUSION: Despite the fairly indolent course of DP-NET liver 
      metastases in MEN1 patients, half of the population was deceased after 10 years. 
      Sex and tumor load at diagnosis of liver metastases are possible prognostic 
      factors for worse survival. ABBREVIATIONS: DMSG = DutchMEN1 Study Group; D-NET = 
      duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; 
      HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine 
      neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = 
      pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit 
      of normal; WHO = World Health Organization.
FAU - Conemans, Elfi B
AU  - Conemans EB
FAU - Nell, Sjoerd
AU  - Nell S
FAU - Pieterman, Carolina R C
AU  - Pieterman CRC
FAU - de Herder, Wouter W
AU  - de Herder WW
FAU - Dekkers, Olaf M
AU  - Dekkers OM
FAU - Hermus, Ad R
AU  - Hermus AR
FAU - van der Horst-Schrivers, Anouk N
AU  - van der Horst-Schrivers AN
FAU - Bisschop, Peter H
AU  - Bisschop PH
FAU - Havekes, Bas
AU  - Havekes B
FAU - Drent, Madeleine L
AU  - Drent ML
FAU - Vriens, Menno R
AU  - Vriens MR
FAU - Valk, Gerlof D
AU  - Valk GD
LA  - eng
PT  - Journal Article
DEP - 20170222
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cause of Death
MH  - Databases, Factual
MH  - Duodenal Neoplasms/*mortality/pathology
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*mortality/secondary
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/*mortality
MH  - Netherlands
MH  - Neuroendocrine Tumors/*mortality/secondary
MH  - Pancreatic Neoplasms/*mortality/pathology
MH  - Prognosis
MH  - Survival Rate
EDAT- 2017/02/23 06:00
MHDA- 2017/09/01 06:00
CRDT- 2017/02/23 06:00
PHST- 2017/02/23 06:00 [pubmed]
PHST- 2017/09/01 06:00 [medline]
PHST- 2017/02/23 06:00 [entrez]
AID - S1530-891X(20)35804-3 [pii]
AID - 10.4158/EP161639.OR [doi]
PST - ppublish
SO  - Endocr Pract. 2017 Jun;23(6):641-648. doi: 10.4158/EP161639.OR. Epub 2017 Feb 22.